[{"id":"8b8fa052-0810-47f2-9451-706b3f201858","acronym":"","url":"https://clinicaltrials.gov/study/NCT01687244","created_at":"2021-01-18T07:19:07.786Z","updated_at":"2024-07-02T16:37:19.647Z","phase":"Phase 2","brief_title":"Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer","source_id_and_acronym":"NCT01687244","lead_sponsor":"FKD Therapies Oy","biomarkers":" IFNA1","pipe":" | ","alterations":" IFNA2 elevation","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNA2 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adstiladrin (nadofaragene firadenovec-vncg)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-07-24"}]